InCube Ventures

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies to address unmet medical needs for patients globally. The company’s flagship technology, Electrical Nerve Block, targets the elimination of chronic pain associated with various conditions, including neuroma, residual limb pain, chronic post-surgical pain, and chronic migraines. Additionally, Neuros Medical offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices designed to enhance treatment outcomes. Founded in 2008, the company aims to provide innovative solutions for chronic pain management.

Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.

Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.

Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.

WhiteSwell Limited provides cardiology services. The company offers treatment for acute decompensated hearth failure (ADHF). Its treatment is a catheter-based approach to remove excess tissue fluid in patients with ADHF, without comprising renal function. The company was founded in 2014 and is based in Galway, Ireland with additional offices in Shefayim, Israel and Palo Alto, California

Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.

Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.

Plexuss, Inc. operates an online platform designed to connect students, alumni, and universities around the world. Founded in 2013 and headquartered in Walnut Creek, California, the company provides students with resources for researching colleges and universities, accessing information about scholarships and financial aid, and completing college application assessments for personalized recommendations. In addition, Plexuss facilitates networking among students and alumni, enhancing their educational experience. The platform utilizes advanced technologies, including matching algorithms and big data analytics, to help students find compatible post-secondary educational opportunities and engage with relevant content. Through its Global Student Network, Plexuss aims to create meaningful connections that enable students to access transformative educational experiences.

Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.

Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.

Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.

BodyMedia, founded in 1999 and based in Pittsburgh, PA, specializes in wearable body monitoring devices that gather physiological data to enhance health, wellness, and fitness. The company offers a range of continuous on-body monitors that utilize proprietary technology validated for clinical accuracy. These devices serve both consumers and health professionals, facilitating behavioral adjustments aimed at weight management and active living—critical factors in addressing serious health issues. BodyMedia's products include a calorie management system that tracks calories burned against those consumed, alongside body monitoring systems that record various physiological metrics analyzed through its SenseWear software. The company has contributed significantly to health research, participating in over 100 clinical studies related to obesity, diabetes, and other medical conditions, thereby creating one of the largest databases of human physiological information.

IntraPace, Inc. specializes in the development and marketing of implantable devices aimed at treating obesity. Founded in 2001 and located in Mountain View, California, the company has created the abiliti system, which stimulates a satiety response to facilitate weight loss. This innovative device is based on technology commonly used in cardiac pacemakers and defibrillators, allowing for implantation through standard laparoscopic methods. Notably, the abiliti system does not alter the digestive system's anatomy and imposes no restrictions on a patient's dietary intake, making it a versatile option for individuals seeking weight management solutions.

Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

Sonoma Orthopedic Products specializes in the design, development, and delivery of proprietary orthopedic implants aimed at assisting physicians in the treatment of problematic fractures. The company's innovative WaviBody technology platform facilitates quick and minimally invasive surgical solutions, catering to the needs of active patients. By focusing on advanced orthopedic solutions, Sonoma Orthopedic Products aims to enhance patient recovery and overall quality of care.

Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

Action Pharma A/S develops novel drugs for cardio vascular treatment. The company also conducts pre-clinical and early clinical trials of new pharmaceutical products and treatment concepts for cardiovascular, inflammatory, and acquired metabolic diseases. Its products include COMPOUND AP1189, an oral anti-inflammatory compound under development for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and COMPOUND AP405, a modified MSH peptide analogue under development for the treatment of inflammatory skin diseases, such as atopic dermatitis. Action Pharma A/S was founded in 2000 and is based in Aarhus, Denmark.